Breaking News

IriSys Doubles Contract with NCI for Mfg. Clinical Trial Materials

The contract is for development and production of new therapeutic agents for use in clinical trials supported by NCI

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

IriSys, a San Diego, CA-based provider of contract pharmaceutical product development and manufacturing services, was awarded an increase in the ceiling of its five-year prime vendor contract, which was doubled to up to $6,000,000, by the National Cancer Institute (NCI)’s Developmental Therapeutics Program (DTP) of the Division of Cancer Treatment and Diagnosis (DCTD). The contract is for the pharmaceutical development and production of new therapeutic agents for use in clinical trials sup...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters